Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Rotigotine
Strength: 4 g
Dosage form: parche transdérmico
Route: vía transdérmica
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 20 Apr 2006
Registration: 05331005
Marketing authorisation holder: Ucb Pharma
Procedure: EU centralised
Supply: Medicamento Sujeto A Prescripción Médica

Spain

Dariante 3 MG/24 Horas Parches Transdérmicos EfgRotigotine · 5,52 mg/24 h · parche transdérmicoSpain

Dariante 4 MG/24 Horas Parches Transdérmicos EfgRotigotine · 7,36 mg/24 h · parche transdérmicoSpain

Dariante 6 MG/24 Horas Parches Transdérmicos EfgRotigotine · 11,04 mg/24 h · parche transdérmicoSpain

Dariante 8 MG/24 Horas Parches Transdérmicos EfgRotigotine · 14,72 mg · parche transdérmicoSpain

Neupro 1 MG/24 H Parche TransdermicoRotigotine · 1 mg · parche transdérmicoSpain

Neupro 2 MG/24 H Parche TransdermicoRotigotine · 2 g · parche transdérmicoSpain

Neupro 3 MG/24 H Parche TransdermicoRotigotine · 3 mg · parche transdérmicoSpain

Neupro 6 MG/24 H Parche TransdermicoRotigotine · 6 g · parche transdérmicoSpain

Neupro 8 MG/24 H Parche TransdermicoRotigotine · 8 g · parche transdérmicoSpain

Kinparlev 1 MG/24 H Parche Transdermico EfgRotigotine · 2,2500 mg · parche transdérmicoSpain